Literature DB >> 8898118

Aseptic loosening in cemented custom-made prosthetic replacements for bone tumours of the lower limb.

P S Unwin1, S R Cannon, R J Grimer, H B Kemp, R S Sneath, P S Walker.   

Abstract

We have made a retrospective study of 1001 custom-made prostheses used as replacements after surgery for bone tumours. There were 493 distal femoral, 263 proximal femoral and 245 proximal tibial prostheses. Aseptic loosening was shown to be the principal mode of failure of the implants, and 71 patients had revision for aseptic loosening of a cemented intramedullary stem. The probability of a patient surviving aseptic loosening for 120 months was 93.8% for a proximal femoral replacement, 67.4% for a distal femoral prosthesis and 58% for a proximal tibial implant. In patients with distal femoral replacements the age of the patient at the time of operation and the percentage of bone resected were related to the risk of aseptic loosening. Young patients with distal femoral prostheses in whom a high percentage of the femur had been replaced had the poorest prognosis for survival without aseptic loosening. The percentage of bone removed had a significant effect in the proximal tibial replacement group, but the age of the patient did not. By contrast, neither the age nor the percentage of bone removed was a factor after proximal femoral replacement. The significance of these findings is discussed in relation to mechanical factors.

Entities:  

Mesh:

Year:  1996        PMID: 8898118

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  88 in total

1.  Custom megaprosthetic replacement for proximal tibial tumours.

Authors:  Mayil Vahanan Natarajan; A Sivaseelam; G Rajkumar; S H Jaheer Hussain
Journal:  Int Orthop       Date:  2003-06-28       Impact factor: 3.075

2.  Distal femoral osteoarticular allografts: long-term survival, but frequent complications.

Authors:  Patrick C Toy; Jeremy R White; Mark T Scarborough; William F Enneking; C Parker Gibbs
Journal:  Clin Orthop Relat Res       Date:  2010-11       Impact factor: 4.176

Review 3.  Megaprostheses for the treatment of malignant bone tumours of the lower limbs.

Authors:  Christian Heisel; Stefan Kinkel; Ludger Bernd; Volker Ewerbeck
Journal:  Int Orthop       Date:  2006-09-12       Impact factor: 3.075

4.  Early distal femoral endoprosthetic survival: cemented stems versus the Compress implant.

Authors:  A A Bhangu; M J Kramer; R J Grimer; R J O'Donnell
Journal:  Int Orthop       Date:  2006-09-16       Impact factor: 3.075

Review 5.  [Extracorporeal irradiation : Reimplantation of bone segments in the treatment of malignant bone tumours].

Authors:  A H Krieg
Journal:  Orthopade       Date:  2017-08       Impact factor: 1.087

6.  Proximal femur allograft-prosthesis with compression plates and a short stem.

Authors:  D Luis Muscolo; German L Farfalli; Luis A Aponte-Tinao; Miguel A Ayerza
Journal:  Clin Orthop Relat Res       Date:  2009-06-02       Impact factor: 4.176

7.  [Proximal and total femur replacement].

Authors:  P H Pennekamp; D C Wirtz; H R Dürr
Journal:  Oper Orthop Traumatol       Date:  2012-07       Impact factor: 1.154

8.  Long-term outcomes of cement in cement technique for revision endoprosthesis surgery.

Authors:  Nicholas M Bernthal; Vishal Hegde; Stephen D Zoller; Howard Y Park; Jason H Ghodasra; Daniel Johansen; Frederick Eilber; Fritz C Eilber; Chandhanarat Chandhanayingyong; Jeffrey J Eckardt
Journal:  J Surg Oncol       Date:  2017-10-29       Impact factor: 3.454

9.  Limb Salvage Versus Amputation in Conventional Appendicular Osteosarcoma: a Systematic Review.

Authors:  Julio J Jauregui; Vidushan Nadarajah; Joseph Munn; Robert Pivec; Bhaveen H Kapadia; Daniel M Lerman; Aditya V Maheshwari
Journal:  Indian J Surg Oncol       Date:  2018-01-20

10.  Extended intralesional treatment versus resection of low-grade chondrosarcomas.

Authors:  Chad Aarons; Benjamin K Potter; Sheila C Adams; J David Pitcher; H Thomas Temple
Journal:  Clin Orthop Relat Res       Date:  2009-01-14       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.